Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2 2018-05-09 18:59
1